Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cancer. Cuproptosis is suggested to be a novel therapy target for cancer treatment. However, the function of cuproptosis and its key regulator <i>FDX1</i> in ccRCC remains unclear. In this study, we...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/13/10/1725 |
| _version_ | 1797407234620129280 |
|---|---|
| author | Song Zeng He Zhang Di Zhang Xiaopeng Hu Liming Song |
| author_facet | Song Zeng He Zhang Di Zhang Xiaopeng Hu Liming Song |
| author_sort | Song Zeng |
| collection | DOAJ |
| description | Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cancer. Cuproptosis is suggested to be a novel therapy target for cancer treatment. However, the function of cuproptosis and its key regulator <i>FDX1</i> in ccRCC remains unclear. In this study, we adequately explored the prognostic factors, clinicopathological characteristics, and function of <i>FDX1</i> in ccRCC. We found that the expression of <i>FDX1</i> was significantly downregulated in ccRCC samples. Patients with a higher <i>FDX1</i> expression had a significantly better prognosis, including overall survival (OS) (Hazard ratio (HR): 2.54, 95% confidence interval (CI): 1.82–3.53, <i>p</i> < 0.001), disease-specific survival (DSS) (HR: 3.04, 95% CI: 2.04–4.54, <i>p</i> < 0.001), and progression-free survival (PFS) (HR: 2.54, 95% CI: 1.82–3.53, <i>p</i> < 0.001). <i>FDX1</i> was a clinical predictor to stratify patients into the high or low risk of poor survival, independent of conventional clinical features, with the area under the ROC curve (AUC) of 0.658, 0.677, and 0.656 for predicting the 5-year OS, DSS, and PFS. The nomogram model based on <i>FDX1</i> had greater predictive power than other individual prognostic parameters. <i>FDX1</i> mainly participated in the oxidative-related process and mitochondrial respiration-related processes but was not associated with immune infiltration levels. In conclusion, the cuproptosis key regulator <i>FDX1</i> could serve as a potential novel prognostic biomarker for ccRCC patients. |
| first_indexed | 2024-03-09T03:38:40Z |
| format | Article |
| id | doaj.art-a06c5edc9fab46a6a80038b1f7faa508 |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-09T03:38:40Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-a06c5edc9fab46a6a80038b1f7faa5082023-12-03T14:45:01ZengMDPI AGGenes2073-44252022-09-011310172510.3390/genes13101725Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell CarcinomaSong Zeng0He Zhang1Di Zhang2Xiaopeng Hu3Liming Song4Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaBeijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaDepartment of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, ChinaClear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cancer. Cuproptosis is suggested to be a novel therapy target for cancer treatment. However, the function of cuproptosis and its key regulator <i>FDX1</i> in ccRCC remains unclear. In this study, we adequately explored the prognostic factors, clinicopathological characteristics, and function of <i>FDX1</i> in ccRCC. We found that the expression of <i>FDX1</i> was significantly downregulated in ccRCC samples. Patients with a higher <i>FDX1</i> expression had a significantly better prognosis, including overall survival (OS) (Hazard ratio (HR): 2.54, 95% confidence interval (CI): 1.82–3.53, <i>p</i> < 0.001), disease-specific survival (DSS) (HR: 3.04, 95% CI: 2.04–4.54, <i>p</i> < 0.001), and progression-free survival (PFS) (HR: 2.54, 95% CI: 1.82–3.53, <i>p</i> < 0.001). <i>FDX1</i> was a clinical predictor to stratify patients into the high or low risk of poor survival, independent of conventional clinical features, with the area under the ROC curve (AUC) of 0.658, 0.677, and 0.656 for predicting the 5-year OS, DSS, and PFS. The nomogram model based on <i>FDX1</i> had greater predictive power than other individual prognostic parameters. <i>FDX1</i> mainly participated in the oxidative-related process and mitochondrial respiration-related processes but was not associated with immune infiltration levels. In conclusion, the cuproptosis key regulator <i>FDX1</i> could serve as a potential novel prognostic biomarker for ccRCC patients.https://www.mdpi.com/2073-4425/13/10/1725clear cell renal cell carcinoma<i>FDX1</i>cuproptosisbiomarkerprognosis |
| spellingShingle | Song Zeng He Zhang Di Zhang Xiaopeng Hu Liming Song Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma Genes clear cell renal cell carcinoma <i>FDX1</i> cuproptosis biomarker prognosis |
| title | Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma |
| title_full | Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma |
| title_fullStr | Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma |
| title_full_unstemmed | Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma |
| title_short | Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator <i>FDX1</i> in Clear Cell Renal Cell Carcinoma |
| title_sort | prognostic clinicopathological and function of key cuproptosis regulator i fdx1 i in clear cell renal cell carcinoma |
| topic | clear cell renal cell carcinoma <i>FDX1</i> cuproptosis biomarker prognosis |
| url | https://www.mdpi.com/2073-4425/13/10/1725 |
| work_keys_str_mv | AT songzeng prognosticclinicopathologicalandfunctionofkeycuproptosisregulatorifdx1iinclearcellrenalcellcarcinoma AT hezhang prognosticclinicopathologicalandfunctionofkeycuproptosisregulatorifdx1iinclearcellrenalcellcarcinoma AT dizhang prognosticclinicopathologicalandfunctionofkeycuproptosisregulatorifdx1iinclearcellrenalcellcarcinoma AT xiaopenghu prognosticclinicopathologicalandfunctionofkeycuproptosisregulatorifdx1iinclearcellrenalcellcarcinoma AT limingsong prognosticclinicopathologicalandfunctionofkeycuproptosisregulatorifdx1iinclearcellrenalcellcarcinoma |